Biohaven Pharmaceutical Holding Company Ltd.'s first commercial product, Nurtec ODT (rimegepant), is off to a solid start as the first and only CGRP inhibitor with US Food and Drug Administration approval for both acute treatment and prevention of migraine. As Biohaven focuses on expanding the drug’s use in both settings, it is also building out a pipeline of drugs to address additional neurological conditions, as investor focus turns to what comes next.
Nurtec ODT generated $92.9m in second quarter sales, Biohaven reported on 9 August. The drug is the company’s first commercial product, and Biohaven is competing in a crowded category that includes products marketed by bigger pharma rivals, including AbbVie Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?